Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 9/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29506736 | 0.88 | LCK (0.60) | LCKRAB9ACSNK1DLMNANPC1 | |
| SCHEMBL28706165 | 0.88 | LCK (0.60) | LCKRAB9ACSNK1DLMNANPC1 | |
| SCHEMBL20703352 | 0.87 | LCK (0.59) | LCKRAB9ACSNK1DLMNANPC1 | |
| SCHEMBL13035331 | 0.87 | LCK (0.59) | LCKRAB9ACSNK1DLMNANPC1 | |
| SCHEMBL29506738 | 0.85 | LCK (0.69) | LCKRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL17090573 | 0.85 | LCK (0.69) | LCKRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL3943412 | 0.84 | LCK (0.61) | LCKRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL30263005 | 0.84 | LCK (0.61) | LCKRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2666847 | 0.83 | DYRK1A (0.67) | LCKRAB9ADYRK1A | |
| SCHEMBL10118217 | 0.81 | RAB9A (0.76) | LCKRAB9ACSNK1DNPC1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2132178-B1 | JNK INHIBITORS | MERCK SHARP & DOHME (US) | 2015-08-19 | — | — | EP | disclosed |
| US-8278337-B2 | Substituted pyridines that are JNK inhibitors | MERCK SHARP & DOHME (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100179141-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-07-15 | — | — | US | disclosed |
| EP-2134713-A2 | NOVEL JNK INHIBITORS | SCHERING CORPORATION (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2132178-A2 | NOVEL JNK INHIBITORS | SCHERING CORPORATION (US) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008082490-A2 | NOVEL JNK INHIBITORS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008082490-A2 | NOVEL JNK INHIBITORS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008082487-A2 | NOVEL JNK INHIBITORS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179141-A1 | NOVEL JNK INHIBITORS | MAPK1, MAPKAPK5, MAPK15 | LCK 50/4885RAB9A 2236/4885CSNK1D 129/4885 |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | MAPK1, MAPKAPK2, MAP4K2 | LCK 76/4885RAB9A 1965/4885CSNK1D 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.